ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0503

18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis

Kaitlin Quinn1, Mark A. Ahlman2, Hugh Alessi3, Ashkan Malayeri2, Jamie Marko2, Elaine Novakovich2 and Peter Grayson4, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 2National Institutes of Health, Bethesda, MD, 3National Institutes of Health, Bethesda, Maryland, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

Meeting: ACR Convergence 2021

Keywords: FDG-PET, giant cell arteritis, Imaging, longitudinal studies, Takayasu.s arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)

Session Type: Abstract Session

Session Time: 3:45PM-4:00PM

Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of large-vessel vasculitis (LVV). FDG-PET can detect vascular inflammation. Whether vascular PET findings predict angiographic change is unknown.

Methods: Patients with GCA or TAK were recruited into a prospective, observational cohort. All patients underwent magnetic resonance (MR) or computed tomography (CT) angiography and a follow-up study ≥6 months after baseline per a standardized imaging protocol. Arterial lesions, defined as stenosis, occlusion, or aneurysm, were evaluated in 4 segments of the aorta and 13 branch arteries by a central reader blinded to clinical status. Development of new lesions in these same territories was recorded, and existing lesions were characterized as improved, worsened, or unchanged over time.

All patients underwent FDG-PET on the same date as angiography. Qualitative assessment of FDG uptake was performed in each corresponding arterial territory evaluated by angiography. Active vasculitis was defined as greater FDG uptake in the arterial wall compared to the liver by visual inspection.

Conditional logistic regression using a within-person matched design selecting for cases of asymmetric angiographic progression in paired arterial territories (e.g. bilateral subclavian arteries) was performed to evaluate whether FDG-PET activity was independently associated with angiographic progression, controlling for all person-level confounders.

Results: 1162 arterial territories were evaluated from 70 patients with LVV (TAK=38; GCA=32). Over 1.6 years of median follow-up, new lesions developed only in 8 arterial territories, exclusively in 5 patients with TAK. Arterial lesions improved in 16 territories (GCA = 7, TAK = 9) and worsened in 6 territories (GCA = 1, TAK = 5). Typically, angiographic change was asymmetric in paired arteries (26/30 territories).

FDG-PET activity was evaluated in 1091/1162 (94%) of corresponding arterial territories. PET activity in an arterial territory at baseline was significantly associated with change in that arterial territory on follow-up angiography (p< 0.01), with a sensitivity of 80% and specificity of 74% (FIGURE). Most arterial territories without PET activity at baseline remained unchanged over time by angiography, yielding a negative predictive value of 99%. Most territories with PET activity also did not show change over time, but of the territories with angiographic change, the majority had PET activity (24/30 territories). Using conditional logistic regression, an arterial territory with baseline PET activity had a 3-fold increased risk for angiographic progression of disease compared to the paired arterial territory without PET activity (p< 0.01).

Conclusion: Development of angiographic change was infrequent in this cohort of patients with LVV. Lack of PET activity was strongly associated with stable angiographic disease. Most cases of angiographic change were asymmetric in paired arterial territories with PET activity present only in the affected side at baseline. These data may inform recommendations for imaging monitoring in LVV.


Disclosures: K. Quinn, None; M. Ahlman, None; H. Alessi, None; A. Malayeri, None; J. Marko, None; E. Novakovich, None; P. Grayson, None.

To cite this abstract in AMA style:

Quinn K, Ahlman M, Alessi H, Malayeri A, Marko J, Novakovich E, Grayson P. 18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/18f-fluorodeoxyglucose-positron-emission-tomography-as-a-predictor-of-angiographic-progression-of-disease-in-large-vessel-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/18f-fluorodeoxyglucose-positron-emission-tomography-as-a-predictor-of-angiographic-progression-of-disease-in-large-vessel-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology